0.05Open0.05Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover698.58%IV1473.21%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2779Delta0.5723Gamma6.42Leverage Ratio-0.0039Theta0.0000Rho1.78Eff Leverage0.0003Vega
Biomerica Stock Discussion
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
Biomerica (NASDAQ: BMRA) has secured three key patent allowances in European markets for its inFoods® Technology, targeting GERD, Crohn's Disease, and Ulcerative Colitis. The patents cover major European markets including Germany, UK, France, Italy, Spain, and over 30 other EPO nations. These markets represent significant opportunities: GERD ...
just
Biomerica Secures Three Key International Patents for Infoods® Technology to Address Gerd, Crohn’s Disease, and Ulcerative Colitis
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements
They don't seem to know how to sell the news.
The Saudi Food and Drug Authority (Sfda) Approves Biomerica's at Home Psa Screening Test to Detect Early Signs of Prostate Cancer
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
Biomerica (Nasdaq: BMRA) has launched an at-home sample collection system for its inFoods® IBS diagnostic test, enhancing patient convenience and expanding access to millions of IBS sufferers. Using a simple finger-stick method, patients can now self-collect blood samples at home, eliminating the need for healthcare facility visits. This innovation ...
biggest but signal I've ever seen
No comment yet